Latest Period
Q1 2026
Security Snapshot
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) Institutional Ownership
CUSIP: 98943L107
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
100
Shares (Excl. Options)
43,560,789
Price
$2.34
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock,$0.001 par value per share
- Symbol
- ZNTL on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 43,560,789
- Total 13F value
- $101,671,381
- Portfolio coverage rank
- 0%
- Share change
- +2,849,494
- Value change
- +$8,469,947
- Number of holders
- 100
- Shares outstanding
- 72,096,078
- SEC-reported price per share
- $4.06
- Insider filing price
- $4.06
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share is tracked under CUSIP 98943L107.
- 100 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 85 to 100 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $54,747,323 to $101,671,381.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 100 institutions filings for Q1 2026.
Security key
98943L107
Latest holder period
Q1 2026
13F holders
100
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
ZNTL full holder history
Zentalis Pharmaceuticals, Inc. SEC filings
Zentalis Pharmaceuticals, Inc. company facts
Zentalis Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98943L107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
ZNTL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| WALTERS GROUP | 20% | $20,264,960 | 13,509,973 | Walters William T | 31 Dec 2025 | |||
| Walters William T | 9.9% | +8.9% | $10,081,500 | +$786,500 | 7,050,000 | +8.5% | Walters William T | 29 Jan 2025 |
| 5AM Opportunities II (GP), LLC | 6.4% | $7,257,856 | 4,838,571 | Andrew J. Schwab | 18 Dec 2025 | |||
| BARCLAYS PLC | 5.3% | $5,800,588 | 3,841,449 | Barclays PLC | 30 Sep 2025 | |||
| Squadron Capital Management LLC | 5.1% | $9,376,095 | 3,676,900 | Squadron Master Fund LP | 24 Feb 2026 | |||
| VANGUARD GROUP INC | 4.6% | $4,677,873 | 3,271,240 | The Vanguard Group | 31 Dec 2024 | |||
| BlackRock, Inc. | 2.2% | $1,952,121 | 1,613,323 | BlackRock, Inc. | 30 Jun 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 1.3% | -80% | $1,272,555 | -$4,059,076 | 902,521 | -76% | Millennium Management LLC | 30 Sep 2025 |
| FMR LLC | 0.2% | $251,484 | 175,863 | FMR LLC | 29 Nov 2024 |
As of 31 Mar 2026, 100 institutional investors reported holding 43,560,789 shares of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL). This represents 60% of the company’s total 72,096,078 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
50%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 5.5% | 3,947,913 | 0% | 2.6% | $9,238,116 |
| Squadron Capital Management LLC | 5% | 3,631,000 | 3.4% | $8,496,540 | |
| TWO SIGMA INVESTMENTS, LP | 4.1% | 2,956,526 | +101% | 0.01% | $6,918,271 |
| ACADIAN ASSET MANAGEMENT LLC | 4% | 2,848,252 | -0.04% | 0.01% | $6,658,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 2,310,707 | 0% | 0% | $5,407,054 |
| RENAISSANCE TECHNOLOGIES LLC | 2.7% | 1,938,145 | -33% | 0.01% | $4,535,259 |
| CITADEL ADVISORS LLC | 2.4% | 1,732,083 | -12% | 0% | $4,053,074 |
| D. E. Shaw & Co., Inc. | 2.1% | 1,484,098 | -11% | 0% | $3,472,789 |
| Opaleye Management Inc. | 2% | 1,412,656 | +0.84% | 0.46% | $3,305,615 |
| Decheng Capital LLC | 1.8% | 1,323,327 | 0% | 0.47% | $3,096,585 |
| MILLENNIUM MANAGEMENT LLC | 1.8% | 1,289,822 | +92% | 0% | $3,018,183 |
| BlackRock, Inc. | 1.8% | 1,269,837 | +1.6% | 0% | $2,971,419 |
| Ishara Investments LP | 1.7% | 1,230,000 | -6.8% | 2.9% | $2,878,200 |
| BANK OF AMERICA CORP /DE/ | 1.6% | 1,132,294 | -17% | 0% | $2,649,568 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.3% | 957,420 | 0% | 0% | $2,240,363 |
| Pfizer Inc | 1.3% | 953,834 | 0% | 0.84% | $2,003,051 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.1% | 792,001 | +0.63% | 0% | $1,853,282 |
| Qube Research & Technologies Ltd | 0.88% | 637,116 | +3547% | 0% | $1,490,851 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.86% | 621,036 | +5.4% | 0% | $1,454,005 |
| GSA CAPITAL PARTNERS LLP | 0.86% | 620,407 | -47% | 0.09% | $1,452,000 |
| Almitas Capital LLC | 0.85% | 610,073 | 0% | 0.32% | $1,427,571 |
| BARCLAYS PLC | 0.82% | 591,217 | +4% | 0% | $1,383,448 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.79% | 571,257 | +5423% | 0% | $1,336,741 |
| JANE STREET GROUP, LLC | 0.68% | 490,339 | +3.6% | 0% | $1,147,393 |
| BNP PARIBAS FINANCIAL MARKETS | 0.65% | 471,438 | 0% | 0% | $1,103,165 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 43,560,789 | $101,671,381 | +$8,469,947 | $2.34 | 100 |
| 2025 Q4 | 40,517,312 | $54,747,323 | -$20,028,376 | $1.35 | 85 |
| 2025 Q3 | 52,751,330 | $79,656,235 | -$3,936,309 | $1.51 | 96 |
| 2025 Q2 | 55,655,238 | $64,573,024 | -$4,209,380 | $1.16 | 115 |
| 2025 Q1 | 58,450,755 | $92,928,558 | -$20,527,901 | $1.59 | 131 |
| 2024 Q4 | 64,418,043 | $195,184,400 | -$24,736,255 | $3.03 | 141 |
| 2024 Q3 | 70,964,067 | $261,154,970 | -$21,635,153 | $3.68 | 133 |
| 2024 Q2 | 76,565,937 | $313,165,477 | -$54,359,485 | $4.09 | 142 |
| 2024 Q1 | 85,290,558 | $1,344,227,610 | +$67,005,140 | $15.76 | 140 |
| 2023 Q4 | 81,068,438 | $1,228,198,230 | -$21,970,408 | $15.15 | 118 |
| 2023 Q3 | 80,197,042 | $1,608,751,464 | -$51,643,382 | $20.06 | 136 |
| 2023 Q2 | 82,228,758 | $2,319,672,532 | +$442,954,370 | $28.21 | 131 |
| 2023 Q1 | 67,021,594 | $1,152,767,927 | +$44,945,526 | $17.20 | 108 |
| 2022 Q4 | 64,360,813 | $1,296,145,033 | +$105,231,060 | $20.14 | 106 |
| 2022 Q3 | 58,811,479 | $1,273,846,102 | -$54,003,564 | $21.66 | 116 |
| 2022 Q2 | 58,254,677 | $1,636,896,016 | +$359,446,058 | $28.10 | 115 |
| 2022 Q1 | 44,437,538 | $2,050,628,439 | +$49,057,461 | $46.14 | 123 |
| 2021 Q4 | 42,987,158 | $3,611,907,936 | +$90,022,119 | $84.06 | 134 |
| 2021 Q3 | 41,250,292 | $2,749,252,645 | +$115,288,600 | $66.64 | 114 |
| 2021 Q2 | 39,699,603 | $2,112,018,735 | +$205,833,024 | $53.20 | 117 |
| 2021 Q1 | 36,327,192 | $1,576,156,109 | -$55,960,381 | $43.39 | 93 |
| 2020 Q4 | 37,299,066 | $1,937,340,198 | +$309,645,949 | $51.94 | 104 |
| 2020 Q3 | 31,635,340 | $1,033,195,545 | +$169,604,096 | $32.69 | 65 |
| 2020 Q2 | 26,858,048 | $1,282,608,905 | +$1,282,608,902 | $48.02 | 61 |